Health Stocks in Motion

Updated from 2:22 p.m.

Shares of Genta ( GNTA) were among the worst-performing health and pharmaceutical stocks Tuesday, falling 50% after the biopharmaceutical company said Sanofi-Aventis ( SNY) ended the companies' joint development agreement.

The two companies will work together to develop Genasense, Genta's cancer drug, until May 8, 2005. After that, Genta will continue the development of the drug on its own. When the companies first entered the agreement in 2002, Aventis was seeking a late-stage development opportunity that could potentially be launched in the near term. Earlier this year, however, regulators rejected the drug with respect to melanoma. As a result, Aventis said that it could no longer support the development of Genasense. Shares of Genta traded down $1.30 to $1.30.

Fonar ( FONR) rose 9.7% after the maker of MRI equipment swung to a first-quarter profit. The company posted a profit of 1 cent a share on sales of $25.1 million. A year ago the company posted a loss of 5 cents a share on sales of $13.3 million. Strong sales of the company's Upright MRI units led to the impressive first-quarter results. Shares traded up 11 cents to $1.25.

Shares of BriteSmile ( BSML) fell 16.7% after the company posted weak third-quarter results and warned of a fourth-quarter shortfall as well. During the third quarter, the teeth-whitening technology company posted a loss of 24 cents a share on sales of $11.9 million. Analysts were expecting a loss of 9 cents a share on sales of $12.7 million. Looking ahead, BriteSmile forecast that fourth-quarter sales would decline both sequentially and on a year-over-year basis. Analysts had been expecting sales of $14.7 million. BriteSmile said the sales shortfall reflects soft demand experienced during the first part of the fourth quarter. Shares traded down $1.50 to $7.50.

Salix Pharmaceuticals ( SLXP) rose 12.8% after the company posted third-quarter earnings and sales well above expectations. The pharmaceutical products company earned 19 cents a share on sales of $33.5 million. Analysts were expecting earnings of 14 cents a share on sales of $29.4 million. A year ago the company posted a loss of 12 cents a share on sales of $14.1 million. Shares traded up $2.05 to $18.08.

Other health care volume movers included Merck ( MRK), down 57 cents to $26; Pfizer ( PFE), down 25 cents to $27.99; Anthem ( ATH), up $4.73 to $91.23; WellPoint ( WLP), up $8.93 to $113.90; and StemCells ( STEM), down 28 cents to $3.11.

More from Stocks

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Facebook CEO Mark Zuckerberg Deflects Tough Questions From European Parliament

Facebook CEO Mark Zuckerberg Deflects Tough Questions From European Parliament

What Does China's Tariff Deal Mean for Automakers Like Tesla?

What Does China's Tariff Deal Mean for Automakers Like Tesla?

Lowe's Taps Home Depot Veteran As New CEO

Lowe's Taps Home Depot Veteran As New CEO